News

Public · Published

HIMS Stock Tumbles After-Hours On Surprise Q3 Loss And Cut Profit Outlook: Retail Demands Answers

Hims & Hers reported a $33.0 million third-quarter net loss, compared with $15.8 million net income a year earlier, as revenue rose 49% to $890.4 million. Gross margin, the share of revenue left after direct costs, fell to 57% from 74%, and the company reduced its full-year adjusted core profit outlook.

Published:

Updated:

What happened

Hims & Hers reported a $33.0 million third-quarter net loss, compared with $15.8 million net income a year earlier, as revenue rose 49% to $890.4 million. Gross margin, the share of revenue left after direct costs, fell to 57% from 74%, and the company reduced its full-year adjusted core profit outlook.

Confirmed

Global impact / market context

The shift toward branded drugs and international expansion costs reduced the share of sales left after direct costs. If that mix continues while revenue grows, profit may lag sales growth; lower expected core profit could also limit cash available for expansion or increase pressure to control costs.

Analyst inference

The reported figures show strong revenue and subscriber growth alongside a quarterly loss and sharply lower gross margin. This contrast matters because investors assessing a growing telehealth business must weigh expansion against its cost and the profitability of branded offerings, particularly weight-loss drugs.

Analyst inference

What to watch

  1. Check the complete revised full-year adjusted core profit outlook when available; the supplied article says it was reduced but does not provide the updated profit figure. Confirmed
  2. Watch whether branded-drug sales and international expansion costs continue to weigh on gross margin, which measures the share of sales remaining after direct costs. Analyst inference
  3. Compare future revenue growth with subscriber numbers and monthly revenue per subscriber to see whether customer expansion is translating into stronger profit, not just higher sales. Analyst inference

Evidence